Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT07637019Not yet recruiting
Randomised, double-blind trial in precocious puberty comparing Sanghe Jianghuo Granules with Placebo (2 arms). Primary endpoint: Breast Nodule Regression Rate at 12 weeks. Planned start Jul 2026; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT07637019.